methyl farnesoate: RN given refers to cpd without isomeric designation [MeSH]
methyl farnesoate : A member of the juvenile hormone family of compounds that is the methyl ester of farnesoic acid. Found in several species of crustaceans. [CHeBI]
ID Source | ID |
---|---|
PubMed CID | 5275508 |
CHEMBL ID | 171329 |
SCHEMBL ID | 2023438 |
CHEBI ID | 80535 |
MeSH ID | M0101251 |
Synonym |
---|
2,6,10-dodecatrienoic acid, 3,7,11-trimethyl-, methyl ester, (2e,6e)- |
methyl (2e,6e)-3,7,11-trimethyldodeca-2,6,10-trienoate |
2,6,10-dodecatrienoic acid, 3,7,11-trimethyl-, methyl ester |
farnesyl methyl ester |
methyl (2e,6e)-farnesoate |
10485-70-8 |
methyl farnesoate |
(2e,6e)-3,7,11-trimethyl-dodeca-2,6,10-trienoic acid methyl ester |
methyl (trans,trans)-farnesoate |
(trans,trans)-2,6,10-dodecatrienoic acid, 3,7,11-trimethyl-, methyl ester |
2,6,10-dodecatrienoic acid, 3,7,11-trimethyl-, methyl ester, (e,e)- |
methyl (2-trans-6-trans)-farnesoate |
(2e,6e)-farnesyl methyl ester |
methyl (2e,6e)-3,7,11-trimethyl-2,6,10-dodecatrienoate |
CHEMBL171329 |
chebi:80535 , |
3675-00-1 |
(2e,6e)-methyl 3,7,11-trimethyldodeca-2,6,10-trienoate |
methyl 3,7,11-trimethyl-2,6,10-dodecatrienoate |
methyl (2-trans,6-trans)-farnesoate |
methyl (e,e)-farnesate |
methyl farnesate |
2-trans-farnesic acid methyl ester |
methyl 3,7,11-trimethyl-2e,6e,10-dodecatrienoate |
methyl (e,e)-farnesoate |
methyl trans,trans-farnesate |
methyl trans,trans-farnesoate |
methyl (2e,6e)-3,7,11-trimethyl-2,6,10-dodecatrienoate # |
methyl trans,trans-farnesenate |
NWKXNIPBVLQYAB-VDQVFBMKSA-N |
methyl (2e,6e)-farnesate |
SCHEMBL2023438 |
(e,e)-methyl farnesoate |
(2e,6e)-methyl3,7,11-trimethyldodeca-2,6,10-trienoate |
DTXSID80893654 |
Q27149580 |
a methyl farnesoate |
Role | Description |
---|---|
crustacean metabolite | An animal metabolite produced by arthropods such as crabs, lobsters, crayfish, shrimps and krill. |
Class | Description |
---|---|
juvenile hormone | A family of farnesane sesquiterpenoids that regulate many aspects of insect physiology. |
enoate ester | An alpha,beta-unsaturated carboxylic ester of general formula R(1)R(2)C=CR(3)-C(=O)OR(4) (R(4) =/= H) in which the ester C=O function is conjugated to a C=C double bond at the alpha,beta position. |
fatty acid methyl ester | A fatty acid ester that is the carboxylic ester obtained by the formal condensation of a fatty acid with methanol. |
methyl farnesoate is involved in 1 pathway(s), involving a total of 4 unique proteins and 39 unique compounds
Pathway | Proteins | Compounds |
---|---|---|
juvenile hormone III biosynthesis I | 0 | 17 |
juvenile hormone III biosynthesis I | 4 | 22 |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID47224 | In vitro inhibition of yeast cell growth of candida albicans; No inhibition | 2002 | Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6 ISSN: 0960-894X | Evaluation of morphogenic regulatory activity of farnesoic acid and its derivatives against Candida albicans dimorphism. |
AID47226 | In vitro inhibition of yeast-to-hypha transition in candida albicans; No inhibition | 2002 | Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6 ISSN: 0960-894X | Evaluation of morphogenic regulatory activity of farnesoic acid and its derivatives against Candida albicans dimorphism. |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (1.71) | 18.7374 |
1990's | 21 (17.95) | 18.2507 |
2000's | 41 (35.04) | 29.6817 |
2010's | 45 (38.46) | 24.3611 |
2020's | 8 (6.84) | 2.80 |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 5 (4.10%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 117 (95.90%) | 84.16% |
Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
carcinine | beta-alanine derivative; imidazoles; monocarboxylic acid amide; organonitrogen compound; organooxygen compound | antioxidant; crustacean metabolite | 0 | 0 | low | 0 | 0 | 0 | 0 | 0 | 0 |
Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
farnesol | farnesol | plant metabolite | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
farnesoic acid | farnesoic acid | animal metabolite | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
decaprenoic acid | alpha,beta-unsaturated monocarboxylic acid; methyl-branched fatty acid; monoterpenoid; polyunsaturated fatty acid | antifungal agent; EC 1.14.18.1 (tyrosinase) inhibitor; melanin synthesis inhibitor; pheromone; plant metabolite | 2002 | 2002 | 22.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 | |
geranylgeranic acid | alpha,beta-unsaturated monocarboxylic acid; diterpenoid; methyl-branched fatty acid; trienoic fatty acid | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
46,XX Gonadal Dysgenesis, Complete, Sry-Positive | 0 | 2006 | 2006 | 18.0 | high | 0 | 0 | 0 | 1 | 0 | 0 | |
Ambiguous Genitalia | 0 | 2006 | 2006 | 18.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 | |
Disorders of Sex Development | 0 | 2006 | 2006 | 18.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 | |
Polyploid | 0 | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
Sensitivity and Specificity | 0 | 2017 | 2017 | 7.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
Article | Year |
---|---|
Comparative ovarian microarray analysis of juvenile hormone-responsive genes in water flea Daphnia magna: potential targets for toxicity. Journal of applied toxicology : JAT, , Volume: 37, Issue:3 | 2017 |
Article | Year |
---|---|
Effect of methyl farnesoate, alone and in combination with other hormones, on ovarian growth of the red swamp crayfish, Procambarus clarkii, during vitellogenesis. General and comparative endocrinology, , Volume: 125, Issue:1 | 2002 |